Nerandomilast-Jascayd is a medicine that treats what

Nerandomilast - Jascayd is a drug used to treat idiopathic pulmonary fibrosis (IPF) in adults. The drug acts as an inhibitor of phosphodiesterase 4 (PDE4). Idiopathic pulmonary fibrosis is a common progressive fibrotic interstitial lung disease whose cause is unknown. Its main symptoms include dyspnea during activity, persistent dry cough, fatigue and weakness.

The main component of nerandomilastnerandomilast exerts its efficacy by selectively inhibiting the PDE4B enzyme. The PDE4 enzyme is responsible for hydrolyzing and inactivating cyclic adenosine monophosphate (cAMP), and nomilast increases intracellular cAMP levels by inhibiting the activity of PDE4B, thereby reducing the expression of profibrotic growth factors and inflammatory cytokines. These factors are often overexpressed in patients with idiopathic pulmonary fibrosis, and therefore, the use of namilast may help alleviate the pulmonary fibrosis associated with the condition.

The U.S. Food and Drug Administration (FDA) referred to the results of two randomized, double-blind, placebo-controlled clinical trials when approving nomilast. The primary endpoint of these trials is the absolute change from baseline in forced vital capacity (FVC), which is the maximum volume a person can forcefully exhale after inhaling as deeply as possible. The study found that patients taking namilast had a significantly smaller decrease in FVC than patients in the placebo group, indicating that namilast has a significant effect in delaying the decline of lung function.

Namilast is taken in tablet form by mouth twice daily, usually about12 hours apart. In terms of side effects, common adverse reactions (incidence ≥5%) include diarrhea, COVID-19, upper respiratory tract infection, depression, weight loss, decreased appetite, nausea, fatigue, headache, vomiting, back pain and dizziness. This information is of great significance for doctors to formulate corresponding monitoring and management strategies when using namilast clinically.

Reference materials:https://www.drugs.com/jascayd.html